New Zealand’s Roadside Drug Testing: 300 Tests, 7 Fines.
New Zealand’s roadside drug testing programme is new, cautious, and — if international comparisons are anything to go by — only scratching the surface of a problem that is significantly larger than the official numbers currently suggest.
Since police began testing drivers in the Wellington region in December 2025, around 300 people have been tested and seven infringement notices issued. That is a detection rate of roughly 2.3%. On the surface, that might sound reassuring. But compare it to what police in New South Wales achieved in a single four-day operation — 9,000 drug tests, 604 alleged drug drivers detected, a detection rate of 6.7% — and the picture looks very different.
This is not a reflection of New Zealand having less drug use. It is a reflection of a programme still finding its feet, with nationwide rollout not expected until mid-2026. The implication is clear: drug-impaired driving on New Zealand roads is almost certainly far more common than our current enforcement figures reveal.
| 7 Infringements — New Zealand ~300 tests • 2 months • Wellington only | 604 Drug Drivers Detected — NSW 9,000+ tests • 4 days • state-wide operation |
NZ detection rate: ~2.3% vs NSW detection rate: ~6.7%
The Numbers at a Glance
| Measure | 🇳🇿 New Zealand | 🇦🇺 NSW, Australia |
| Tests conducted | ~300 | 9,000+ |
| Timeframe | 2 months | 4 days |
| Drug infringements | 7 | 604 |
| Drink driving | Not separated | 167 detected |
| Detection rate | ~2.3% | ~6.7% |
| Breath tests | Ongoing | 12,000 |
| Total infringements | Not published | 6,500 |
| Coverage | Wellington only | State-wide |
| Nationwide rollout | Mid-2026 (planned) | Long established |
Source: RNZ News, 20 February 2026 — ‘Seven drugged drivers fined since roadside testing began’. rnz.co.nz/news/national/587456
The Scale Problem — And What It Really Means
It is tempting to look at seven infringements and conclude that drug-impaired driving is a minor issue in New Zealand. But the more relevant comparison is the rate at which drug-impaired drivers are being detected relative to the volume of testing.
New South Wales has been running roadside drug testing for years. Their programme is mature, their testing volumes are high, and their enforcement operations are well-resourced. In a single four-day blitz, they tested more than 9,000 drivers and found that roughly 1 in every 15 had drugs in their system. They also issued 6,500 traffic infringements in total — including 12,000 breath tests — in a coordinated effort to tackle impaired driving at scale.
New Zealand, by contrast, is still in the pilot phase. Testing only began in Wellington in December 2025 and will not reach the rest of the country until mid-2026. The low number of infringements to date does not mean the problem is small — it means the testing volume is small.
| The key question is not “how many fines were issued?” — it’s “how many impaired drivers are out there that we haven’t tested yet?” If New Zealand were to run a comparable operation to NSW — 9,000 tests over four days — the same detection rate would suggest we might expect to find over 200 impaired drivers in a single operation. That is a sobering thought. |
What Drugs Are Being Tested — And What Drivers Need to Know
New Zealand’s roadside drug testing currently screens drivers for four substances: cannabis, methamphetamine, MDMA, and cocaine. Testing is conducted using oral fluid (saliva) samples with Drugwipe 3S collected at the roadside.
One important clarification that has caused public confusion: a prescription does not protect you. As NZ Police have made clear, drivers cannot use a prescription or medical note to avoid taking a test or to dispute a positive result. The test measures the presence of a drug — not whether you had permission to take it. If a prescribed medication impairs your ability to drive safely, you should not be driving, regardless of the prescription.
This is particularly relevant for medicinal cannabis users, thousands of whom have raised concerns about the new laws. The message from police is unambiguous: know what you are taking, understand how it affects your driving, and do not get behind the wheel during any period where it is unsafe to drive.
| “If you intend to get behind the wheel after consuming impairing drugs, you will be caught.” — Superintendent Steve Greally, Director of Road Policing, NZ Police (February 2026) |
Why This Matters Beyond the Road
Drug-impaired driving is, by definition, a workplace issue for anyone whose job involves driving or operating machinery. A worker who drives to a job site under the influence of drugs or alcohol does not become unimpaired the moment they arrive. The same impairment that endangers other road users endangers colleagues, the public, and the worker themselves once they begin work.
This is why the roadside data matters to employers — particularly those in industries where safety-sensitive work is the norm. The NSW data suggests that at any given time, a meaningful proportion of people on the roads have drugs in their system. Workers are not exempt from that proportion.
The Case for Workplace Drug Testing
Roadside enforcement, however effective, is reactive. It catches impaired drivers after they have already driven. Workplace drug testing — specifically oral fluid screening — adds a proactive layer of protection that roadside testing cannot provide.
For industries with safety-sensitive roles — construction, roading, utilities, local government services, transport — the stakes are high. An impaired worker operating heavy machinery, driving a vehicle, or working at height presents a risk that a roadside checkpoint at 7am simply cannot address.
Oral fluid testing used in workplace programmes follows the same methodology as roadside testing and Drugwipe 5s , 6S uses the same technology as the device used by NZ police:it is non-invasive, fast, and detects recent drug use accurately. The same substances screened on the roadside — cannabis, methamphetamine, MDMA, cocaine, and others — can be screened in the workplace, with confirmatory laboratory testing available where required.
| Proactive Workplace testing catches impairment before an incident occurs. Roadside testing catches it after the driver has already been on the road. | Proportionate Random oral fluid testing is non-invasive, dignified, and consistent with the approach used by police on public roads. | Defensible IANZ-accredited laboratory confirmation ensures that any action taken is based on verified, scientifically sound results. |
What a Good Workplace Drug Testing Programme Looks Like
As New Zealand’s roadside enforcement landscape evolves, employers have an opportunity — and in many sectors, a legal obligation under the Health and Safety at Work Act 2015 — to ensure their workplace is free from the risks that drug and alcohol impairment creates.
A well-designed workplace drug testing programme typically includes:
- A clear, written policy that covers what substances are prohibited, in what circumstances testing will occur, and the consequences of a positive result or refusal to test.
- Pre-employment testing for safety-sensitive roles, ensuring new workers enter the workplace without undisclosed impairment.
- Random testing, using a genuinely random selection process, to provide an ongoing deterrent and duty-of-care mechanism.
- Post-incident testing, conducted as soon as practicable after any workplace accident or near-miss, to establish whether impairment was a contributing factor.
- Reasonable cause testing, where observable indicators suggest a worker may be impaired.
- A rehabilitation pathway, so that workers who are struggling with substance use are supported, not simply punished.
- MRO (Medical Review Officer) review of all confirmed positive results, to ensure that medications are properly considered before any employment decision is made.
Oral fluid testing is the preferred method for workplace screening in most contexts — it is the same method used by NZ Police for roadside testing, it detects recent drug use, it is harder to adulterate than urine, and it can be conducted on-site by trained personnel without the need for private collection facilities.
A Word on Medicinal Cannabis and Prescription Medications
One of the most frequently asked questions we receive from employers — and increasingly from employees — is: “What happens if someone has a prescription?”
The answer, both on the road and in the workplace, is the same: a prescription does not mean a person is fit to drive or fit to work. It means a medical professional has authorised the use of a particular substance for a particular purpose. It does not override the obligation to be safe.
For employers, this means that workplace drug policies need to include clear provisions around prescription medication disclosure — particularly for medicinal cannabis, which is now more widely available in New Zealand and is detectable in oral fluid for days to weeks after use, depending on the individual and the dose.
Workers in safety-sensitive roles should be required to disclose any prescribed medication that may affect their ability to work safely, before they begin work or as soon as a new prescription is issued. Employers, in consultation with the worker and relevant health professionals, can then put in place appropriate risk mitigation — whether that is a temporary change of duties, additional monitoring, or a review with a Medical Review Officer.
| The principle is straightforward: You have a right to your medication. You do not have a right to put others at risk because of it. This applies equally on public roads and in the workplace. |
What Comes Next for New Zealand
NZ Police have confirmed that roadside drug testing will expand nationwide by mid-2026. This means that by the middle of this year, any driver anywhere in New Zealand may be subject to a roadside oral fluid test. The Wellington pilot has already demonstrated that the technology works and that the public response — from both motorists and police — has been positive.
As enforcement scales up, detection numbers will rise. The NSW comparison gives us a reasonable basis to expect that, once New Zealand is running testing at meaningful volume, the number of drug-impaired drivers detected will be substantially higher than current figures suggest.
For employers, particularly those in sectors with safety-sensitive roles, this is a strong signal. The community expectation — and increasingly the legal and regulatory expectation — is that workplaces are drug and alcohol free. The roadside programme reinforces that expectation, not replaces it.
Workplace drug testing and roadside enforcement work best together. Police catch impaired drivers on the road. Employers — with the right policies and testing programmes in place — ensure those same standards apply once workers arrive on site.
Contact us if you would like to use the same technology as devive used by NZ Police and have assurance that the product works accurately.
| About Advance Diagnostics Advance Diagnostics is a New Zealand-based drug and alcohol testing specialist, providing workplace testing solutions, policy development support, and training to employers across a range of industries. We use IANZ-accredited laboratory confirmation for all non-negative results, and provide MRO review services to ensure outcomes are fair, defensible, and evidence-based. advancediagnostics.co.nz |
References
RNZ News (20 February 2026). ‘Seven drugged drivers fined since roadside testing began.’ rnz.co.nz/news/national/587456
NSW Police (2026). Operation data as referenced in public reporting — New South Wales four-day traffic enforcement operation.
NZ Police, Superintendent Steve Greally, Director of Road Policing — public statements, February 2026.